{"id":"W2495752760","doi":"10.1186/s13063-016-1466-2","title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial","year":2016,"lang":"en","type":"article","venue":"Trials","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"UCB Pharma; Seventh Framework Programme; Genentech; Grifols; GBS/CIDP Foundation International; Glenmark Pharmaceuticals; Myasthenia Gravis Foundation of America; AstraZeneca; CSL Behring; Argenx; GlaxoSmithKline; European Commission; Acorda Therapeutics; Pfizer","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Randomized controlled trial; Protocol (science); Antibody; Immunology; Physical therapy; Bioinformatics; Internal medicine; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01001579,0.0004242683,0.00361334,0.000111104,0.0001824487,0.00004478953,0.0001926831,0.00007871716,0.00005119089],"category_scores_gemma":[0.01150585,0.0001754044,0.001076748,0.000124666,0.0001001529,0.00005709465,0.00004062616,0.0001024226,0.000005382407],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004042143,"about_ca_system_score_gemma":0.0006205067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008359975,"about_ca_topic_score_gemma":0.0002080825,"domain_scores_codex":[0.9930792,0.002949151,0.002513649,0.0005445189,0.0003264349,0.0005870522],"domain_scores_gemma":[0.9894268,0.008832704,0.000984565,0.0005056824,0.0001677414,0.00008251116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9846896,0.002485918,0.0001581834,0.00004876329,0.0004183674,0.0000934112,0.0007702644,0.00001239544,0.001828384,0.00004101531,0.0001023516,0.009351361],"study_design_scores_gemma":[0.9673368,0.02842962,0.00006230783,0.0001366345,0.0006180227,0.0000105549,0.0007953162,0.0003638628,0.00006356963,0.0001989536,0.001784415,0.0001999134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.326013,0.00006096848,0.0003148624,0.0004606809,0.000273694,0.6727726,0.00001234055,0.00005831954,0.00003349255],"genre_scores_gemma":[0.4068261,0.00001171,0.00002821429,0.00007100911,0.0004470969,0.5919267,9.527245e-7,0.0000393506,0.000648893],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.080846,"threshold_uncertainty_score":0.9968206,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04971943532551758,"score_gpt":0.3810367955733524,"score_spread":0.3313173602478348,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}